• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

    83.49 +0.26 (+0.31%)
    Streaming Delayed Price Updated: 9:46 AM EDT, Aug 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Halozyme Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    News headline image
    What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings
    Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Thursday after the bell. Here’s what to ... 
    Via StockStory
    News headline image
    3 Growth Stocks Set to Flourish
    Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
    Via StockStory
    News headline image
    1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
    While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
    Via StockStory
    Topics Energy
    News headline image
    1 Value Stock Worth Investigating and 2 Facing Headwinds
    The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
    Via StockStory
    Halozyme Therapeutics (NASDAQ:HALO): A Value Stock Profile Offering Strong Profitability and a Low Forward P/E ↗
    Via Chartmill
    Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E ↗
    Via Chartmill
    Halozyme Therapeutics (NASDAQ:HALO) Surges After Q1 Beat, Launches $1 Billion Buyback ↗
    Via Chartmill
    Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗
    Via Chartmill
    News headline image
    2 Reasons to Like HALO and 1 to Stay Skeptical
    Halozyme Therapeutics trades at $78.57 and has moved in lockstep with the market. Its shares have returned 8.5% over the last six months while the S&P 500 ha... 
    Via StockStory
    Topics Stocks
    News headline image
    1 Surging Stock for Long-Term Investors and 2 We Brush Off
    Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements... 
    Via StockStory
    News headline image
    2 Profitable Stocks Worth Your Attention and 1 We Question
    While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
    Via StockStory
    Topics Credit Cards
    News headline image
    Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today
    What Happened? Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 5.2% in the afternoon session after an analyst re... 
    Via StockStory
    Topics Economy
    Halozyme Therapeutics Inc (NASDAQ:HALO) Reports Mixed Q4 2025 Results with Revenue Beat and Unexpected Loss ↗
    Via Chartmill
    HALOZYME THERAPEUTICS INC (NASDAQ:HALO): A GARP Stock with Strong Growth and Reasonable Valuation ↗
    Via Chartmill
    News headline image
    Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions
    Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the exp... 
    Via StockStory
    Topics Earnings
    News headline image
    Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
    What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi... 
    Via StockStory
    Topics Economy
    News headline image
    Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)
    The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook
    Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up ... 
    Via StockStory
    News headline image
    Halozyme (HALO) Q1 2026 Earnings Transcript ↗
    Halozyme (HALO) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Halozyme Therapeutics Q1 Earnings Call Highlights ↗
    Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Halozyme Therapeutics’s (NASDAQ:HALO) Q1 CY2026 Sales Top Estimates
    Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up ... 
    Via StockStory
    News headline image
    Halozyme Therapeutics Earnings: What To Look For From HALO
    Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Monday after market close. Here’s what t... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That Underwhelm
    Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
    Via StockStory
    News headline image
    3 Cash-Producing Stocks with Exciting Potential
    Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain ... 
    Via StockStory
    News headline image
    2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore
    Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
    Via StockStory
    News headline image
    1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off
    Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
    Via StockStory
    News headline image
    Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
    As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Haloz... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    2 Reasons to Like HALO (and 1 Not So Much)
    Since August 2025, Halozyme Therapeutics has been in a holding pattern, posting a small loss of 2.1% while floating around $70.71. The stock also fell short of the S&P 500’s 6.2% gain during that... 
    Via StockStory
    Topics Stocks
    News headline image
    Halozyme (HALO) Q4 2025 Earnings Call Transcript ↗
    Halozyme (HALO) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales
    Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 51.6% year on year to $451.8 million. The... 
    Via StockStory
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.